About
Artrya Ltd is an Australian medical technology company based in West Perth, specializing in artificial intelligence solutions for cardiovascular healthcare. Founded in 2018, Artrya focuses on developing AI-driven platforms that enhance the detection, diagnosis, and management of coronary artery disease (CAD), a major cause of heart attacks. The company's flagship product, Salix, is a cloud-based software suite that automates the analysis of coronary computed tomography angiography (CCTA) scans. Salix helps clinicians identify and characterize arterial plaque, improving the efficiency and accuracy of CAD assessments. This technology supports healthcare providers, particularly clinics treating patients with chest pain, by offering actionable insights into arterial health and facilitating timely interventions. Artrya collaborates with healthcare delivery systems globally to set new standards in cardiac diagnostics. Their software is registered on the Australian Register of Therapeutic Goods, ensuring compliance with medical device regulations. Key executives include Co-Founder and CEO John Konstantopoulos, Executive Chair Bernard William Ridgeway, and Chief Scientific Officer Prof. Girish Dwivedi.
Technologies
Keywords
Company Information
-
Employees 49
-
Founded 2018
-
Annual Revenue $18000
-
Total Funding $55000000
Location
88 Broadway, Perth, Western Australia, Australia, 6009